Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, Locatelli F, Gorriz JL, Rutkowski B, Ferreira A, Bos WJ, Covic A, Rodríguez-García M, Sánchez JE, Rodríguez-Puyol D, Cannata-Andia JB; COSMOS group. Fernández-Martín JL, et al. Among authors: dionisi mp. Nephrol Dial Transplant. 2015 Sep;30(9):1542-51. doi: 10.1093/ndt/gfv099. Epub 2015 Apr 28. Nephrol Dial Transplant. 2015. PMID: 25920921 Clinical Trial.
Bone and mineral metabolism at 55 haemodialysis centres in Lima.
Méndez-Chacón P, Riccobelli N, Dionisi MP, Sánchez-Álvarez E, Bardales-Viguria F, Méndez-Chacón Rodríguez C, Cannata-Andía JB, Fernández-Martín JL. Méndez-Chacón P, et al. Among authors: dionisi mp. Nefrologia (Engl Ed). 2018 May-Jun;38(3):279-285. doi: 10.1016/j.nefro.2017.09.011. Nefrologia (Engl Ed). 2018. PMID: 29731011 Free article. English, Spanish.
Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study.
Fernández-Martín JL, Dusso A, Martínez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, Locatelli F, Górriz JL, Rutkowski B, Bos WJ, Tielemans C, Martin PY, Wüthrich RP, Pavlovic D, Benedik M, Rodríguez-Puyol D, Carrero JJ, Zoccali C, Cannata-Andía JB; COSMOS group. Fernández-Martín JL, et al. Among authors: dionisi mp. Nephrol Dial Transplant. 2019 Apr 1;34(4):673-681. doi: 10.1093/ndt/gfy093. Nephrol Dial Transplant. 2019. PMID: 29741651
Emerging concepts on the FGF23 regulation and activity.
Rivoira MA, Peralta López ME, Areco V, Díaz de Barboza G, Dionisi MP, Tolosa de Talamoni N. Rivoira MA, et al. Among authors: dionisi mp. Mol Cell Biochem. 2024 Apr 6. doi: 10.1007/s11010-024-04982-6. Online ahead of print. Mol Cell Biochem. 2024. PMID: 38581553 Review.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.